A phase I COVID-19 vaccine trial among SARS-CoV-2 seronegative and seropositive individuals in Uganda utilizing a self-amplifying RNA vaccine platform: Screening and enrollment experiences (2023)
Attributed to:
Future Vaccine Manufacturing Hub: Advancing the manufacture and deployment of cost effective vaccines
funded by
EPSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1080/21645515.2023.2240690
PubMed Identifier: 37553178
Publication URI: http://europepmc.org/abstract/MED/37553178
Type: Journal Article/Review
Parent Publication: Human Vaccines & Immunotherapeutics
Issue: 2
ISSN: 2164-5515